ABSTRACT: A new family of organometallic p-cymene ruthenium(II) and osmium(II) complexes conjugated to ethacrynic acid, a glutathione transferase (GST) inhibitor, is reported. The ethacrynic acid moiety (either one or two) is tethered to the arene ruthenium(II) and osmium(II) fragments via strongly coordinating modified bipyridine ligands. The solid-state structure of one of the complexes, i.e. [Os(η 6 -p-cymene)Cl][(4′-methyl-[2,2′-bipyridin]-4-yl)-methyl-2-(2,3-dichloro-4-(2-methylenebutanoyl)phenoxy)acetate]Cl, was established by single-crystal X-ray diffraction, corroborating the expected structure. The complexes are efficient inhibitors of GST P1-1, an enzyme expressed in cancer cells and implicated in drug resistance, and are cytotoxic to the GST-overexpressing chemoresistant A2780cisR ovarian cancer cell line.
■ INTRODUCTION
Resistance to chemotherapy, either intrinsic or acquired, remains a serious obstacle in cancer treatment. Drug resistance is a multifactorial process, and several basic mechanisms have been identified, including enhanced drug efflux associated with the P-glycoprotein, enhanced repair of drug-induced injury, and enhanced detoxification of drug intermediates, frequently related to intracellular glutathione (GSH) and GSH-associated enzymes. 1−4 In particular, the overexpression of glutathione transferases (GSTs) and efflux pumps in cancer cells reduces the efficacy of various anticancer drugs, 1−4 and the search for compounds capable of inhibiting GSTs and/or efflux pumps is key to overcoming resistance to anticancer drugs.
GSTs are a family of homo-and heterodimeric cytosolic enzymes that catalyze the conjugation of GSH with a variety of exogenous and endogenous electrophiles and, consequently, are involved in the inactivation of various electrophile-producing anticancer agents. The products, in the form of mercapturates, are subsequently eliminated from the cell. 5 As GSH and the GST superfamily play an important role in the mechanism of anticancer drug resistance, 2,6−8 including metal-based drugs, 9−15 efforts have focused on the development of GST inhibitors and GST-activated prodrugs as means of sensitizing drug-resistant cancer cells to treatment. 16−18 In this context, ethacrynic acid ([2,3-dichloro-4-(2-methylene-1-oxobutyl)-phenoxyl]acetic acid, EA-H; Figure 1 ) is a versatile, watersoluble compound that modulates GST activity. EA-H conjugation to GSH may occur in a spontaneous fashion or via the catalytic action of the major classes of GST (α, μ, and π), with the π isozyme being the most active. 19 EA-H potentiates the in vitro cytotoxicity of chemotherapeutic agents, including alkylating agents such as melfalan, 20−23 carmustine, 24 mitomycin C, 25 nitrogen mustards, 17, 26 and chlorambucil. 19, 27 EA-H induced sensitization of tumor cells to doxorubicin 26, 28 or cisplatin 20, 29, 30 has also been reported. It was suggested that EA-H may modulate the drug resistance of tumor cells not only by inhibiting GST activity but also by inhibiting the export of GSH conjugates of drugs from the cell by the multidrug resistance protein. 31 Platinum-based cancer drugs, such as cisplatin, are highly effective chemotherapeutic agents used extensively for the treatment of solid tumors. Nevertheless, drug resistance is a major obstacle for platinum-based chemotherapy, frequently attributed to GSH-mediated detoxification. GST enzymes, specifically GST-π isozymes, are overexpressed in cisplatinresistant cell lines, and the inhibition of these enzymes can lead to the reversal of drug resistance, as the combination of cisplatin with EA-H resulted in improved activity against cisplatin-resistant cells. 20, 29, 30 The codelivery of EA-H and DACHPt (a precursor of oxaliplatin) using biodegradable nanoparticles results in an enhancement of the anticancer efficacy. 32 In vivo, the nanoparticles demonstrated greater anticancer efficacy and less systemic toxicity, in comparison to a combination therapy involving the free drugs. 32 Recently, GST inhibitor−anticancer drug conjugates have been reported, such as ethacraplatin, a platinum(IV) metallodrug with two tethered EA-H moieties. 33−35 Ethacraplatin is a stronger inhibitor of GST activity in live mammalian cells in comparison to either cisplatin or EA-H alone, 33 and the complex was shown to reverse cisplatin resistance in the microsomal-GST-over-expressing MCF7 cell line. 36 Platinum(II)−EA conjugates have been also reported. 34 Ruthenium compounds are promising alternatives to classical platinum-based derivatives, and various ruthenium(III) and ruthenium(II) complexes have been reported to exhibit relevant antitumor activity. Figure 1 ) show considerable promise as anticancer drugs in a number of preclinical models. Osmium-(II)-based analogues of these compounds have also been reported and show promising anticancer properties. 48, 49 One strategy used to modulate the medicinal properties of ruthenium(II) arene complexes (and related osmium compounds) is to tether a functional bioactive molecule to the metal framework. 50−57 Since bifunctional RAPTA-like compounds modified with EA show promise as both GST inhibitors and anticancer agents (Figure 1) , 33 
■ RESULTS AND DISCUSSION
The compounds described in this study were prepared according to the routes shown in Schemes 1 and 2. Bipyridine derivatives were modified with either one or two EA units (it has been shown that organic compounds containing two EA units are potent inhibitors of GST 63, 64 ). The route to the bipyridine ligand with one EA moiety, i.e. L1, involves the direct reaction of EA-H with 4-hydroxymethyl-4′-methyl-2,2′- The ligands and complexes were fully characterized by 1 H and 13 C NMR spectroscopy, mass spectrometry, IR spectroscopy and elemental analysis (see the Experimental Section for full details). The asymmetric bidentate ligand L1 induces chirality at the metal center in 1a,b, resulting in loss of the 2-fold symmetry of the η 6 -p-cymene moiety, 65 and thus, 1a,b were obtained as a racemic mixture.
The 1 H NMR spectra of 1a,b contain four separate doublets corresponding to the aromatic protons of the p-cymene ring and two doublets attributable to the isopropyl group, one for each methyl group, these resonances revealing the stereogenic and chirotopic nature of the metal center (local C 1 symmetry). 65 The 1 H NMR spectra of ligand L1 and the corresponding complexes 1a,b exhibit peaks which show that the protons α to the N atoms of the bipyridine unit are strongly influenced by coordination to the metal ion; for L1 peaks corresponding to the α protons appear at 8.65 and 8.53 ppm and are observed at 9.41 and 9.28 ppm in 1a and at 9.34 and 9.22 ppm in 1b (for all of the compounds the signals observed at higher frequencies may be attributed to the EA-modified pyridine ring, whereas the peaks at lower frequencies correspond to the pyridine ring substituted with the methyl group). For the corresponding C atoms a similar shift to higher frequencies is observed upon coordination of L1 (L1, 150.3 and 149.7 ppm; 1a, 156.7 and 156.1 ppm; 1b, 156.1 and 156.0 ppm). Coordination of ligand L2 to the metal centers leads to a shift of all the peaks corresponding to the pyridine rings to higher frequencies.
The structure of the compounds was further confirmed by electrospray ionization mass spectrometry. The crystal structure of 1b was established in the solid state by single-crystal X-ray diffraction (Figure 2 ), confirming the expected structure. The structure comprises the classical threelegged piano-stool arrangement. The coordination sphere of the Os(II) ion contains an η 6 -p-cymene ring, the bidentate ligand, and a chloride ligand. The average Os−η 6 centroid distance is 1.675(4) Å. The bipyridine ligand forms essentially a planar five-membered chelating ring, the two pyridine rings of the bipyridne ligands being almost coplanar (dihedral angle N1-C-C−N2 2.2(11)°) ( Figure S1 ). The the chelate bite angle N1−Os−N2 is 76.6(3)°, and the N1−Os−Cl and N2−Os−Cl angles are 84.6(2) and 86.1(2)°, respectively. The Os−N py bond lengths are 2.090(7) Å (for Os−N1) and 2.103(7) Å (for Os−N2), and the Os−Cl bond length is 2.404(3) Å. The packing in the crystal comprises intermolecular paralleldisplaced π−π stacking interactions between the bipyridine ligands of two adjacent molecules (centroid−centroid distance 3.955 Å, Figure S2 in the Supporting Information). Another key interaction in 1b comprises a three-center hydrogen bond between the chloride counteranion (acting as a bifurcated acceptor) and the hydrogen atoms of CH 3 OH and CHCl 3 solvent molecules (see Figure S4 and Table S1 in the Supporting Information for the parameters characterizing the hydrogen bonding interaction).
Human GST P1-1 used for the experiments was expressed in and purified from E. coli using a protocol reported earlier. 66, 67 The inhibitory activity of the compounds was investigated by determining the residual catalytic activity of the enzyme using the CDNB-GSH (1-chloro-2,4-dinitrobenzene−glutathione) assay. 68 In brief, the enzyme was treated with varying concentrations of complexes 1a,b and 2a,b to determine the IC 50 value i.e., the concentration at which 50% enzyme activity is inhibited.
Complexes 1a,b (containing only one pendant ethacrynic acid unit) inhibit GST P1-1 activity slightly more efficiently than EA-H 58 (see Table 1 ). Notably, complexes 2a,b, containing two EA units, are more potent inhibitors of GST P1-1. Furthermore, treatment with 2b results in almost complete inhibition of GST P1-1 activity (residual activity <5%) at the highest concentration tested (100 μm), whereas there is more significant residual GST P1-1 activity (∼14%) after treatment with 1a,b at the same concentration (see Figure  S7 in the Supporting Information). These findings suggest a role of the organometallic ruthenium fragment in the inhibition of GST P1-1, potentially involving direct coordination of the metal ion to the enzyme as established previously. 58 The cytotoxicity of ligands L1 and L2, complexes 1a,b and 2a,b, and relevant control compounds was assessed in two cancer cell lines (human ovarian carcinoma cisplatin-sensitive A2780 and -resistant A2780cisR) and human embryonic kidney (HEK-293) cells used as a model for normal cells. Cytotoxicity studies were carried out at 37°C for 72 h (Table 2 and Figure  S8 in the Supporting Information) using an MTT test (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) to monitor cell viability. All of the complexes are more cytotoxic than RAPTA-C 69 Interestingly, ligand L1, derivatized with one EA unit, has a higher antiproliferative activity in comparison to EA-H on all the tested cell lines, whereas attachment of two EA units in L2 is accompanied by a significant decrease in cytotoxicity.
Attachment of an organometallic M II -p-cymene moiety to L2 in 2a,b leads to a significant increase in the antiproliferative activity toward all tested cell lines. The ruthenium complex with two EA moieties, 2a, displays very similar IC 50 values in both the A2780 and A2780cisR cell lines (7.77 and 8.37 μM, respectively), and the Os analogue is slightly less cytotoxic with values of 9.31 and 15.7 μM, respectively. However, 2a,b are both cytotoxic to the nontumorigenic HEK-293 cells with IC 50 values of 6.16 and 12.8 μM, respectively. The relatively potent cyctotoxicity of 2a,b cannot be attributed entirely to the ability of the complexes to inhibit GST activity but is presumably also in part due to the increased hydrophobicity of the complexes relative to RAPTA-C and OAPTA-C, which potentially enhances drug uptake and, consequently, their cytotoxic effects. Overall, complexes 1a,b are less cytotoxic in all three cell lines than 2a,b. Since the former pair are chiral but obtained as a racemic mixture, it is possible that the individual optical isomers present different antiproliferative activities. Indeed, it has been previously shown that different optical isomers of chiral-atmetal or chiral-at-ligand ruthenium(II) and Os(II) arene complexes may or may not exhibit similar cytotoxicities. 70−73 Interestingly, in all three cell lines, for the Ru/Os pair 1a,b the osmium complex is more cyctotoxic, whereas for the pair 2a,b the ruthenium complex presents higher antiproliferative activity. Such a difference is not entirely unexpected, as there appears to be no clear correlation from the multitude of studies reporting analogues based on these two metals. 74 
■ CONCLUSIONS
In summary, we have shown that incorporation of organometallic p-cymene ruthenium(II) or osmium(II) centers to EAderived compounds enhances the inhibition of GST P1-1 activity, an enzyme expressed in cancer cells and responsible for drug resistance. The enhanced inhibition is particularly notable for 2a,b, in which the metal ion is located between two EA moieties. These two compounds are also the most cytotoxic of the series, displaying similar antiproliferative activity to both A2780 and A2780cisR cells, indicative of overcoming GST-type resistance in the latter cell line which is known to overexpress GSTs. 11 Interestingly, while there is no difference between the pairs of ruthenium and osmium complexes in terms of GST P1-1 inhibition and only a slight difference with respect to antiproliferative activity, the metal ions appear to play a critical role, i.e. in comparison to the free ligands, implying that direct interactions with the enzyme might be involved. 76 and coupling constants (J) are reported in hertz (Hz). IR spectra were recorded on a PerkinElmer Spectrum One FT-IR spectrometer at room temperature. Electrospray ionization mass spectra (ESI-MS) were obtained on a Thermo-Finnigan LCQ Deca XP Plus quadropole ion-trap instrument operated in positive-ion mode. Elemental analyses were carried out by the microanalytical laboratory at the Institute of Chemical Sciences and Engineering (EPFL). Melting points were determined using a SMP3 Stuart Melting Point Apparatus and are uncorrected. Reactions were monitored by TLC using Merck TLC silica gel coated aluminum sheets 60 F 254 and visualized with UV at 254 nm and KMnO 4 stain. Compounds were purified by column flash chromatography on silica gel using the elution systems indicated. 
Syntheses of the Ligands. Synthesis of (4′-Methyl-[2,2′-bipyridin]-4-yl)methyl-2-(2,3-dichloro-4-(2-methylenebutanoyl)-phenoxy)acetate (L1).

S y n t h e s i s o f 2 -H y d r o x y e t h yl -2 -( 2 , 3 -d i c h l o r o -4 -(2 -methylenebutanoyl)phenoxy)acetate (L2a).
To a solution of ethacynic acid (4.000 g, 1 equiv) in CH 2 Cl 2 (mL) were added EDCI (3.035 g, 1.2 equiv), ethylene glycol (3 mL, 4 equiv), and DMAP (0.322 g, 0.2 equiv). The reaction mixture was stirred at room temperature for 24 h, and then the mixture was diluted with CH 2 Cl 2 (50 mL) and washed with H 2 O (150 mL) and the isolated organic phase was further washed with brine (150 mL), dried over anhydrous Na 2 SO 4 , filtered, and concentrated under reduced pressure. Purification by flash column chromatography using a Hex/EtOAc mixture as eluent afforded the product as a white solid ( Bruker APEX II CCD diffractometer equipped with a κ geometry goniometer.
The data sets were reduced by EvalCCD 77 and then corrected for absorption. 78 The solution and refinement were performed by SHELXT and SHELXL2014 (release 7). 79 The crystal structures were refined using full-matrix least squares based on F 2 with all nonhydrogen atoms anisotropically defined. Hydrogen atoms were placed in calculated positions by means of the "riding" model. Additional electron density found in the difference Fourier map of the compound (due to disordered solvent) was treated by the SQUEEZE algorithm of PLATON 80 and then treated by the ABIN instruction in SHELXL2014. Crystal data and structure refinement details are given in Table 3 .
Protein Expression and Purification. Human GST P1-1 wildtype was expressed in Escherichia coli and purified as previously described. 66 The reaction was monitored by spectrophotometry at 340 nm, corresponding to the absorbance maximum of glutathione-2,4-dinitrobenzene conjugate (ε 340 = 9.6 M −1 cm −1 ). 81 Spectrophotometric measurements were performed using a double-beam Cary UV− vis 4000 spectrophotometer (Kontron Instruments) equipped with a thermostated cuvette compartment.
GST P1-1 Inhibition Assay. The residual enzymatic activity of GST P1-1 was assayed by spectrophotometry in 100 mM phosphate buffer, pH 6.5, in the presence of variable amounts of compound 1a, Organometallics Article 1b, 2a, or 2b (from 1 to 100 μM), predissolved in DMSO, 1 mM GSH (glutathione), and 1 mM CDNB (1-chloro-2,4-dinitrobenzene), at 25°C . The IC 50 values for the inhibition of GST P1-1 were determined by fitting a plot of residual GST activity against the inhibitor concentrations with a sigmoidal dose−response function using Graph PAD Prism (Graph PAD Software, San Diego, CA).
Cell Culture. Human A2780 and A2780cisR ovarian carcinoma cells were obtained from the European Centre of Cell Cultures (ECACC, U.K.). The resistance of the A2780cisR cells was maintained by a monthly treatment with cisplatin (2 μM/one 4 day passage). Nontumorigenic HEK-293 cells were provided by the Institute of Pathology, CHUV, Lausanne, Switzerland. A2780 and A2780cisR were grown in RPMI 1640 medium supplemented with GlutaMAX (Gibco), and HEK-293 cells were grown in DMEM medium, all containing heat-inactivated fetal calf serum (FCS, Sigma, USA) (10%) and antibiotics (penicillin (100 U/mL):streptomycin (100 μg/mL), working concentration 1:100, Life Technologies, Gibco) at 37°C and CO 2 (5%).
Antiproliferative Activity in Vitro. Cytotoxicity was determined using the MTT assay (MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide). Cells were seeded in 96-well plates as monolayers with 100 μL of cell solution per well and preincubated for 24 h in the cell medium. Compounds were prepared as DMSO solutions that were rapidly dissolved in the culture medium and serially diluted to the appropriate concentration to give a final DMSO concentration of 0.5%. A 100 μL portion of the drug solution was added to each well, and the plates were incubated for another 72 h. Subsequently, MTT (5 mg/mL solution) was added to the cells and the plates were incubated for a further 4 h. The culture medium was aspirated, and the purple formazan crystals formed by the mitochondrial dehydrogenase activity of vital cells were dissolved in DMSO. The optical density, directly proportional to the number of surviving cells, was quantified at 540 nm using a multiwell plate reader, and the fraction of surviving cells was calculated from the absorbance of untreated control cells. Evaluation was based on means from two independent experiments, each comprising three microcultures per concentration level.
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